Rein Therapeutics (RNTX) Competitors $1.14 -0.05 (-4.10%) As of 02:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock RNTX vs. COYA, ATOS, MGNX, ZURA, HURA, ANEB, ANIX, VIRI, TCRX, and AVTXShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Coya Therapeutics (COYA), Atossa Genetics (ATOS), MacroGenics (MGNX), Zura Bio (ZURA), TuHURA Biosciences (HURA), Anebulo Pharmaceuticals (ANEB), Anixa Biosciences (ANIX), Virios Therapeutics (VIRI), TScan Therapeutics (TCRX), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Coya Therapeutics Atossa Genetics MacroGenics Zura Bio TuHURA Biosciences Anebulo Pharmaceuticals Anixa Biosciences Virios Therapeutics TScan Therapeutics Avalo Therapeutics Rein Therapeutics (NASDAQ:RNTX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk. Do institutionals and insiders have more ownership in RNTX or COYA? 90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 12.0% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer RNTX or COYA? In the previous week, Coya Therapeutics had 13 more articles in the media than Rein Therapeutics. MarketBeat recorded 16 mentions for Coya Therapeutics and 3 mentions for Rein Therapeutics. Coya Therapeutics' average media sentiment score of -0.01 beat Rein Therapeutics' score of -0.38 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, RNTX or COYA? Coya Therapeutics has higher revenue and earnings than Rein Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.69-0.43Coya Therapeutics$3.55M28.42-$14.88M-$1.24-4.86 Do analysts recommend RNTX or COYA? Coya Therapeutics has a consensus target price of $16.50, indicating a potential upside of 173.59%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RNTX or COYA more profitable? Coya Therapeutics' return on equity of -61.05% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -110.77% -31.89% Coya Therapeutics N/A -61.05%-53.61% Which has more risk and volatility, RNTX or COYA? Rein Therapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. SummaryCoya Therapeutics beats Rein Therapeutics on 10 of the 14 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.39M$3.13B$5.71B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-0.4320.9230.9125.28Price / SalesN/A232.70404.2188.50Price / Cash2.6741.5625.2228.45Price / Book2.669.779.536.01Net Income-$62.88M-$54.74M$3.26B$265.34M7 Day Performance-1.29%8.37%4.66%2.89%1 Month Performance-19.37%7.94%5.35%1.61%1 Year PerformanceN/A18.27%32.14%25.61% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein TherapeuticsN/A$1.15-4.1%N/AN/A$26.39MN/A-0.439Earnings ReportCOYACoya Therapeutics1.6499 of 5 stars$6.08-0.3%$16.50+171.4%+20.1%$102.02M$3.55M-5.686Earnings ReportAnalyst RevisionATOSAtossa Genetics2.6976 of 5 stars$0.79+1.9%$6.17+683.6%-39.3%$101.66MN/A-3.758Earnings ReportAnalyst RevisionMGNXMacroGenics4.3269 of 5 stars$1.54-4.3%$5.40+250.6%-51.1%$101.57M$149.96M-1.73430News CoverageEarnings ReportAnalyst ForecastZURAZura Bio3.7037 of 5 stars$1.42-4.1%$14.33+909.4%-49.4%$101.19MN/A-2.033News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHURATuHURA Biosciences1.7953 of 5 stars$2.30-5.3%$12.67+450.7%N/A$100.46MN/A0.00N/AEarnings ReportANEBAnebulo Pharmaceuticals2.2333 of 5 stars$2.41+0.4%$5.50+128.2%+26.3%$98.60MN/A-9.274ANIXAnixa Biosciences2.7398 of 5 stars$2.98-1.0%$9.00+202.0%-4.5%$96.96M$210K-7.845VIRIVirios TherapeuticsN/A$4.890.0%$5.00+2.2%+2,508.5%$94.17MN/A-18.115Gap DownTCRXTScan Therapeutics3.6654 of 5 stars$1.64-0.6%$7.80+375.6%-68.6%$93.38M$2.82M-1.50100News CoverageEarnings ReportAnalyst RevisionAVTXAvalo Therapeutics3.5939 of 5 stars$8.93+6.9%$30.00+235.9%-0.6%$90.41M$440K0.0040Analyst ForecastShort Interest ↓ Related Companies and Tools Related Companies COYA Competitors ATOS Competitors MGNX Competitors ZURA Competitors HURA Competitors ANEB Competitors ANIX Competitors VIRI Competitors TCRX Competitors AVTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our Partners"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access